Loading…
The PAI‐1 4G/5G polymorphism is not associated with an increased risk of adverse pregnancy outcome in asymptomatic nulliparous women
Background: Plasminogen activator inhibitor type 1 (PAI‐1) is an important regulator of fibrinolysis. A common deletion polymorphism that results in a sequence of 4G instead of 5G in the promoter region of the gene is associated with a small increase in the risk of venous thromboembolism. Its poten...
Saved in:
Published in: | Journal of thrombosis and haemostasis 2012-05, Vol.10 (5), p.881-886 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4190-3d01a84174c1e804ea5c58765609bd484c15f11b04026435d1f579fe907b17563 |
---|---|
cites | cdi_FETCH-LOGICAL-c4190-3d01a84174c1e804ea5c58765609bd484c15f11b04026435d1f579fe907b17563 |
container_end_page | 886 |
container_issue | 5 |
container_start_page | 881 |
container_title | Journal of thrombosis and haemostasis |
container_volume | 10 |
creator | SAID, J. M. TSUI, R. BORG, A. J. HIGGINS, J. R. MOSES, E. K. WALKER, S. P. MONAGLE, P. T. BRENNECKE, S. P. |
description | Background: Plasminogen activator inhibitor type 1 (PAI‐1) is an important regulator of fibrinolysis. A common deletion polymorphism that results in a sequence of 4G instead of 5G in the promoter region of the gene is associated with a small increase in the risk of venous thromboembolism. Its potential association with adverse pregnancy events remains controversial.
Objective: We aimed to assess the impact of the 4G PAI‐1 polymorphism on pregnancy outcomes in women who had no prior history of adverse pregnancy outcomes or personal or family history of venous thromboembolism.
Patients/methods: This study represents a secondary investigation of a prior prospective cohort study investigating the association between inherited thrombophilias and adverse pregnancy events in Australian women. Healthy nulliparous women were recruited to this study prior to 22 weeks gestation. Genotyping for the 4G/5G PAI‐1 gene was performed using Taqman assays in an ABI prism 7700 Sequencer several years after the pregnancy was completed. Pregnancy outcome data were extracted from the medical record. The primary outcome was a composite comprising development of severe pre‐eclampsia, fetal growth restriction, major placental abruption, stillbirth or neonatal death.
Results: Pregnancy outcome data were available in 1733 women who were successfully genotyped for this polymorphism. The primary composite outcome was experienced by 139 women (8% of the cohort). Four hundred and fifty‐nine women (26.5%) were homozygous for the 4G deletion polymorphism, while 890 (51.4%) were heterozygous. Neither homozygosity nor heterozygosity for the PAI‐1 4G polymorphism was associated with the primary composite outcome (homozygous OR = 1.30, 95% CI = 0.81–2.09, P = 0.28, heterozygous OR = 0.84, 95% CI = 0.53–1.31, P = 0.44) or with the individual pregnancy complications.
Conclusion: The PAI‐1 4G polymorphism is not associated with an increase in the risk of serious adverse pregnancy events in asymptomatic nulliparous women. |
doi_str_mv | 10.1111/j.1538-7836.2012.04700.x |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1020510046</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1020510046</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4190-3d01a84174c1e804ea5c58765609bd484c15f11b04026435d1f579fe907b17563</originalsourceid><addsrcrecordid>eNqNkc1O3DAUha2Kqvy0r1B52c2E69jOz4IFQnQAIbWL6dryODcdD0mc2glDdl2x5hl5EpwOsK43vrr-7rF9DiGUQcLiOt0mTPJikRc8S1JgaQIiB0gePpCj94ODt7rk_JAch7AFYKVM4RM5TFPB00zAEXlcbZD-PL9-_vvEqFieyiXtXTO1zvcbG1pqA-3cQHUIzlg9YEV3dthQ3VHbGY86xI634Y66murqHn1A2nv83enOTNSNg3EtRjYqTG0_uFYP1tBubBrba-_GQHcR6D6Tj7VuAn553U_Ir--Xq4urxe2P5fXF-e3CCFbCglfAdCFYLgzDAgRqaWSRZzKDcl2JIrZlzdgaBMTvcVmxWuZljSXka5bLjJ-Qb3vd3rs_I4ZBtTYYbBrdYXyMYpCCZABiRos9arwLwWOtem9b7acIqTkFtVWzwWo2W80pqH8pqIc4-vX1lnHdYvU--GZ7BM72wM42OP23sLpZXc0VfwH2Y5a7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1020510046</pqid></control><display><type>article</type><title>The PAI‐1 4G/5G polymorphism is not associated with an increased risk of adverse pregnancy outcome in asymptomatic nulliparous women</title><source>Free E-Journal (出版社公開部分のみ)</source><creator>SAID, J. M. ; TSUI, R. ; BORG, A. J. ; HIGGINS, J. R. ; MOSES, E. K. ; WALKER, S. P. ; MONAGLE, P. T. ; BRENNECKE, S. P.</creator><creatorcontrib>SAID, J. M. ; TSUI, R. ; BORG, A. J. ; HIGGINS, J. R. ; MOSES, E. K. ; WALKER, S. P. ; MONAGLE, P. T. ; BRENNECKE, S. P.</creatorcontrib><description>Background: Plasminogen activator inhibitor type 1 (PAI‐1) is an important regulator of fibrinolysis. A common deletion polymorphism that results in a sequence of 4G instead of 5G in the promoter region of the gene is associated with a small increase in the risk of venous thromboembolism. Its potential association with adverse pregnancy events remains controversial.
Objective: We aimed to assess the impact of the 4G PAI‐1 polymorphism on pregnancy outcomes in women who had no prior history of adverse pregnancy outcomes or personal or family history of venous thromboembolism.
Patients/methods: This study represents a secondary investigation of a prior prospective cohort study investigating the association between inherited thrombophilias and adverse pregnancy events in Australian women. Healthy nulliparous women were recruited to this study prior to 22 weeks gestation. Genotyping for the 4G/5G PAI‐1 gene was performed using Taqman assays in an ABI prism 7700 Sequencer several years after the pregnancy was completed. Pregnancy outcome data were extracted from the medical record. The primary outcome was a composite comprising development of severe pre‐eclampsia, fetal growth restriction, major placental abruption, stillbirth or neonatal death.
Results: Pregnancy outcome data were available in 1733 women who were successfully genotyped for this polymorphism. The primary composite outcome was experienced by 139 women (8% of the cohort). Four hundred and fifty‐nine women (26.5%) were homozygous for the 4G deletion polymorphism, while 890 (51.4%) were heterozygous. Neither homozygosity nor heterozygosity for the PAI‐1 4G polymorphism was associated with the primary composite outcome (homozygous OR = 1.30, 95% CI = 0.81–2.09, P = 0.28, heterozygous OR = 0.84, 95% CI = 0.53–1.31, P = 0.44) or with the individual pregnancy complications.
Conclusion: The PAI‐1 4G polymorphism is not associated with an increase in the risk of serious adverse pregnancy events in asymptomatic nulliparous women.</description><identifier>ISSN: 1538-7933</identifier><identifier>ISSN: 1538-7836</identifier><identifier>EISSN: 1538-7836</identifier><identifier>DOI: 10.1111/j.1538-7836.2012.04700.x</identifier><identifier>PMID: 22432640</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Abruptio Placentae - blood ; Abruptio Placentae - genetics ; Adult ; Asymptomatic Diseases ; cohort study ; Female ; Fetal Death - blood ; Fetal Death - genetics ; Fetal Growth Retardation - blood ; Fetal Growth Retardation - genetics ; Fibrinolysis - genetics ; Genetic Predisposition to Disease ; Gestational Age ; Heterozygote ; Homozygote ; Humans ; Logistic Models ; nulliparous ; Odds Ratio ; PAI‐1 ; Parity ; Phenotype ; Plasminogen Activator Inhibitor 1 - genetics ; Polymorphism, Genetic ; Pre-Eclampsia - blood ; Pre-Eclampsia - genetics ; Pregnancy ; Pregnancy Complications - blood ; Pregnancy Complications - genetics ; Pregnancy Outcome ; pre‐eclampsia ; Prospective Studies ; Risk Assessment ; Risk Factors ; Stillbirth - genetics ; thrombophilia ; Victoria</subject><ispartof>Journal of thrombosis and haemostasis, 2012-05, Vol.10 (5), p.881-886</ispartof><rights>2012 International Society on Thrombosis and Haemostasis</rights><rights>2012 International Society on Thrombosis and Haemostasis.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4190-3d01a84174c1e804ea5c58765609bd484c15f11b04026435d1f579fe907b17563</citedby><cites>FETCH-LOGICAL-c4190-3d01a84174c1e804ea5c58765609bd484c15f11b04026435d1f579fe907b17563</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22432640$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SAID, J. M.</creatorcontrib><creatorcontrib>TSUI, R.</creatorcontrib><creatorcontrib>BORG, A. J.</creatorcontrib><creatorcontrib>HIGGINS, J. R.</creatorcontrib><creatorcontrib>MOSES, E. K.</creatorcontrib><creatorcontrib>WALKER, S. P.</creatorcontrib><creatorcontrib>MONAGLE, P. T.</creatorcontrib><creatorcontrib>BRENNECKE, S. P.</creatorcontrib><title>The PAI‐1 4G/5G polymorphism is not associated with an increased risk of adverse pregnancy outcome in asymptomatic nulliparous women</title><title>Journal of thrombosis and haemostasis</title><addtitle>J Thromb Haemost</addtitle><description>Background: Plasminogen activator inhibitor type 1 (PAI‐1) is an important regulator of fibrinolysis. A common deletion polymorphism that results in a sequence of 4G instead of 5G in the promoter region of the gene is associated with a small increase in the risk of venous thromboembolism. Its potential association with adverse pregnancy events remains controversial.
Objective: We aimed to assess the impact of the 4G PAI‐1 polymorphism on pregnancy outcomes in women who had no prior history of adverse pregnancy outcomes or personal or family history of venous thromboembolism.
Patients/methods: This study represents a secondary investigation of a prior prospective cohort study investigating the association between inherited thrombophilias and adverse pregnancy events in Australian women. Healthy nulliparous women were recruited to this study prior to 22 weeks gestation. Genotyping for the 4G/5G PAI‐1 gene was performed using Taqman assays in an ABI prism 7700 Sequencer several years after the pregnancy was completed. Pregnancy outcome data were extracted from the medical record. The primary outcome was a composite comprising development of severe pre‐eclampsia, fetal growth restriction, major placental abruption, stillbirth or neonatal death.
Results: Pregnancy outcome data were available in 1733 women who were successfully genotyped for this polymorphism. The primary composite outcome was experienced by 139 women (8% of the cohort). Four hundred and fifty‐nine women (26.5%) were homozygous for the 4G deletion polymorphism, while 890 (51.4%) were heterozygous. Neither homozygosity nor heterozygosity for the PAI‐1 4G polymorphism was associated with the primary composite outcome (homozygous OR = 1.30, 95% CI = 0.81–2.09, P = 0.28, heterozygous OR = 0.84, 95% CI = 0.53–1.31, P = 0.44) or with the individual pregnancy complications.
Conclusion: The PAI‐1 4G polymorphism is not associated with an increase in the risk of serious adverse pregnancy events in asymptomatic nulliparous women.</description><subject>Abruptio Placentae - blood</subject><subject>Abruptio Placentae - genetics</subject><subject>Adult</subject><subject>Asymptomatic Diseases</subject><subject>cohort study</subject><subject>Female</subject><subject>Fetal Death - blood</subject><subject>Fetal Death - genetics</subject><subject>Fetal Growth Retardation - blood</subject><subject>Fetal Growth Retardation - genetics</subject><subject>Fibrinolysis - genetics</subject><subject>Genetic Predisposition to Disease</subject><subject>Gestational Age</subject><subject>Heterozygote</subject><subject>Homozygote</subject><subject>Humans</subject><subject>Logistic Models</subject><subject>nulliparous</subject><subject>Odds Ratio</subject><subject>PAI‐1</subject><subject>Parity</subject><subject>Phenotype</subject><subject>Plasminogen Activator Inhibitor 1 - genetics</subject><subject>Polymorphism, Genetic</subject><subject>Pre-Eclampsia - blood</subject><subject>Pre-Eclampsia - genetics</subject><subject>Pregnancy</subject><subject>Pregnancy Complications - blood</subject><subject>Pregnancy Complications - genetics</subject><subject>Pregnancy Outcome</subject><subject>pre‐eclampsia</subject><subject>Prospective Studies</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Stillbirth - genetics</subject><subject>thrombophilia</subject><subject>Victoria</subject><issn>1538-7933</issn><issn>1538-7836</issn><issn>1538-7836</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqNkc1O3DAUha2Kqvy0r1B52c2E69jOz4IFQnQAIbWL6dryODcdD0mc2glDdl2x5hl5EpwOsK43vrr-7rF9DiGUQcLiOt0mTPJikRc8S1JgaQIiB0gePpCj94ODt7rk_JAch7AFYKVM4RM5TFPB00zAEXlcbZD-PL9-_vvEqFieyiXtXTO1zvcbG1pqA-3cQHUIzlg9YEV3dthQ3VHbGY86xI634Y66murqHn1A2nv83enOTNSNg3EtRjYqTG0_uFYP1tBubBrba-_GQHcR6D6Tj7VuAn553U_Ir--Xq4urxe2P5fXF-e3CCFbCglfAdCFYLgzDAgRqaWSRZzKDcl2JIrZlzdgaBMTvcVmxWuZljSXka5bLjJ-Qb3vd3rs_I4ZBtTYYbBrdYXyMYpCCZABiRos9arwLwWOtem9b7acIqTkFtVWzwWo2W80pqH8pqIc4-vX1lnHdYvU--GZ7BM72wM42OP23sLpZXc0VfwH2Y5a7</recordid><startdate>201205</startdate><enddate>201205</enddate><creator>SAID, J. M.</creator><creator>TSUI, R.</creator><creator>BORG, A. J.</creator><creator>HIGGINS, J. R.</creator><creator>MOSES, E. K.</creator><creator>WALKER, S. P.</creator><creator>MONAGLE, P. T.</creator><creator>BRENNECKE, S. P.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201205</creationdate><title>The PAI‐1 4G/5G polymorphism is not associated with an increased risk of adverse pregnancy outcome in asymptomatic nulliparous women</title><author>SAID, J. M. ; TSUI, R. ; BORG, A. J. ; HIGGINS, J. R. ; MOSES, E. K. ; WALKER, S. P. ; MONAGLE, P. T. ; BRENNECKE, S. P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4190-3d01a84174c1e804ea5c58765609bd484c15f11b04026435d1f579fe907b17563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Abruptio Placentae - blood</topic><topic>Abruptio Placentae - genetics</topic><topic>Adult</topic><topic>Asymptomatic Diseases</topic><topic>cohort study</topic><topic>Female</topic><topic>Fetal Death - blood</topic><topic>Fetal Death - genetics</topic><topic>Fetal Growth Retardation - blood</topic><topic>Fetal Growth Retardation - genetics</topic><topic>Fibrinolysis - genetics</topic><topic>Genetic Predisposition to Disease</topic><topic>Gestational Age</topic><topic>Heterozygote</topic><topic>Homozygote</topic><topic>Humans</topic><topic>Logistic Models</topic><topic>nulliparous</topic><topic>Odds Ratio</topic><topic>PAI‐1</topic><topic>Parity</topic><topic>Phenotype</topic><topic>Plasminogen Activator Inhibitor 1 - genetics</topic><topic>Polymorphism, Genetic</topic><topic>Pre-Eclampsia - blood</topic><topic>Pre-Eclampsia - genetics</topic><topic>Pregnancy</topic><topic>Pregnancy Complications - blood</topic><topic>Pregnancy Complications - genetics</topic><topic>Pregnancy Outcome</topic><topic>pre‐eclampsia</topic><topic>Prospective Studies</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Stillbirth - genetics</topic><topic>thrombophilia</topic><topic>Victoria</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SAID, J. M.</creatorcontrib><creatorcontrib>TSUI, R.</creatorcontrib><creatorcontrib>BORG, A. J.</creatorcontrib><creatorcontrib>HIGGINS, J. R.</creatorcontrib><creatorcontrib>MOSES, E. K.</creatorcontrib><creatorcontrib>WALKER, S. P.</creatorcontrib><creatorcontrib>MONAGLE, P. T.</creatorcontrib><creatorcontrib>BRENNECKE, S. P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SAID, J. M.</au><au>TSUI, R.</au><au>BORG, A. J.</au><au>HIGGINS, J. R.</au><au>MOSES, E. K.</au><au>WALKER, S. P.</au><au>MONAGLE, P. T.</au><au>BRENNECKE, S. P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The PAI‐1 4G/5G polymorphism is not associated with an increased risk of adverse pregnancy outcome in asymptomatic nulliparous women</atitle><jtitle>Journal of thrombosis and haemostasis</jtitle><addtitle>J Thromb Haemost</addtitle><date>2012-05</date><risdate>2012</risdate><volume>10</volume><issue>5</issue><spage>881</spage><epage>886</epage><pages>881-886</pages><issn>1538-7933</issn><issn>1538-7836</issn><eissn>1538-7836</eissn><abstract>Background: Plasminogen activator inhibitor type 1 (PAI‐1) is an important regulator of fibrinolysis. A common deletion polymorphism that results in a sequence of 4G instead of 5G in the promoter region of the gene is associated with a small increase in the risk of venous thromboembolism. Its potential association with adverse pregnancy events remains controversial.
Objective: We aimed to assess the impact of the 4G PAI‐1 polymorphism on pregnancy outcomes in women who had no prior history of adverse pregnancy outcomes or personal or family history of venous thromboembolism.
Patients/methods: This study represents a secondary investigation of a prior prospective cohort study investigating the association between inherited thrombophilias and adverse pregnancy events in Australian women. Healthy nulliparous women were recruited to this study prior to 22 weeks gestation. Genotyping for the 4G/5G PAI‐1 gene was performed using Taqman assays in an ABI prism 7700 Sequencer several years after the pregnancy was completed. Pregnancy outcome data were extracted from the medical record. The primary outcome was a composite comprising development of severe pre‐eclampsia, fetal growth restriction, major placental abruption, stillbirth or neonatal death.
Results: Pregnancy outcome data were available in 1733 women who were successfully genotyped for this polymorphism. The primary composite outcome was experienced by 139 women (8% of the cohort). Four hundred and fifty‐nine women (26.5%) were homozygous for the 4G deletion polymorphism, while 890 (51.4%) were heterozygous. Neither homozygosity nor heterozygosity for the PAI‐1 4G polymorphism was associated with the primary composite outcome (homozygous OR = 1.30, 95% CI = 0.81–2.09, P = 0.28, heterozygous OR = 0.84, 95% CI = 0.53–1.31, P = 0.44) or with the individual pregnancy complications.
Conclusion: The PAI‐1 4G polymorphism is not associated with an increase in the risk of serious adverse pregnancy events in asymptomatic nulliparous women.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>22432640</pmid><doi>10.1111/j.1538-7836.2012.04700.x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1538-7933 |
ispartof | Journal of thrombosis and haemostasis, 2012-05, Vol.10 (5), p.881-886 |
issn | 1538-7933 1538-7836 1538-7836 |
language | eng |
recordid | cdi_proquest_miscellaneous_1020510046 |
source | Free E-Journal (出版社公開部分のみ) |
subjects | Abruptio Placentae - blood Abruptio Placentae - genetics Adult Asymptomatic Diseases cohort study Female Fetal Death - blood Fetal Death - genetics Fetal Growth Retardation - blood Fetal Growth Retardation - genetics Fibrinolysis - genetics Genetic Predisposition to Disease Gestational Age Heterozygote Homozygote Humans Logistic Models nulliparous Odds Ratio PAI‐1 Parity Phenotype Plasminogen Activator Inhibitor 1 - genetics Polymorphism, Genetic Pre-Eclampsia - blood Pre-Eclampsia - genetics Pregnancy Pregnancy Complications - blood Pregnancy Complications - genetics Pregnancy Outcome pre‐eclampsia Prospective Studies Risk Assessment Risk Factors Stillbirth - genetics thrombophilia Victoria |
title | The PAI‐1 4G/5G polymorphism is not associated with an increased risk of adverse pregnancy outcome in asymptomatic nulliparous women |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A40%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20PAI%E2%80%901%204G/5G%20polymorphism%20is%20not%20associated%20with%20an%20increased%20risk%20of%20adverse%20pregnancy%20outcome%20in%20asymptomatic%20nulliparous%20women&rft.jtitle=Journal%20of%20thrombosis%20and%20haemostasis&rft.au=SAID,%20J.%20M.&rft.date=2012-05&rft.volume=10&rft.issue=5&rft.spage=881&rft.epage=886&rft.pages=881-886&rft.issn=1538-7933&rft.eissn=1538-7836&rft_id=info:doi/10.1111/j.1538-7836.2012.04700.x&rft_dat=%3Cproquest_cross%3E1020510046%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4190-3d01a84174c1e804ea5c58765609bd484c15f11b04026435d1f579fe907b17563%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1020510046&rft_id=info:pmid/22432640&rfr_iscdi=true |